Sign In
Buy ENTA
$13.37
+0.710 (+5.61%)
At Close: Jun 22, 2026
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates
10:15pm, Monday, 07'th Nov 2022 Zacks Investment Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of -240% and 91.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
12:45pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
10:20am, Monday, 03'rd Oct 2022 Zacks Investment Research
Smart Beta ETF report for PJP
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
07:00am, Thursday, 01'st Sep 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver disease
Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript
04:00am, Tuesday, 09'th Aug 2022 The Motley Fool
ENTA earnings call for the period ending June 30, 2022.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
09:55pm, Monday, 08'th Aug 2022 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2022 Results - Earnings Call Transcript
09:07pm, Monday, 08'th Aug 2022
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - P
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
07:34pm, Monday, 08'th Aug 2022
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
02:00pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
06:25pm, Monday, 01'st Aug 2022 Benzinga
Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
5
7
0
0
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022
02:06pm, Wednesday, 06'th Jul 2022 Benzinga
Upgrades
According to Wells Fargo, the prior rating for Rocket Companies Inc (NYSE:RKT) was changed from Equal-Weight to Overweight. In the first quarter, Rocket Companies showed an EPS of $0.15, comp
Cases climb in Southeast Asia and Europe in latest week as BA.4 and BA.5 subvariants take hold
12:14pm, Friday, 24'th Jun 2022 MarketWatch
The World Health Organization said COVID cases were lower overall in the week through June 19, but moved higher in Southeast Asia, the Eastern Mediterranean and the European regions as the BA.4 and BA
Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?
10:09am, Friday, 24'th Jun 2022
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m
Enanta Pharmaceuticals, which is developing its own COVID-19 antiviral, says Pfizer infringed on a patent with Paxlovid
11:46am, Thursday, 23'rd Jun 2022 MarketWatch
The biotech is seeking compensation.
